AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05872737 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Parenting Education and Advice
Description: Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
Study NCT06027580 — intervention group
Intervention type: DEVICE
Intervention: SPIO® Core-MAX® Expedition thoracolumbosacral orthosis
Description: SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months
Study NCT06027580 — intervention group
Intervention type: OTHER
Intervention: Standard Care Therapy option
Description: Standard of care Therapy without the use of trunk orthosis
Study NCT04914364 — intervention group
Intervention type: OTHER
Intervention: Balance assessments
Description: There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
Study NCT05635461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424
Description: 150 mg of either tablet or suspension formulation
Study NCT05758168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Addition of Tie-Over Bolster Dressing
Description: Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
Study NCT04031105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study
Study NCT06527469 — intervention group
Intervention type: OTHER
Intervention: PhysZou emPOWER: a strength, power, and gait intervention group physical therapy program for children with CP
Description: Each session will include a 10-minute game-based warm-up, 45 minutes of gait interventions to include treadmill and overground walking as well as other aerobic activities, 45 minutes of resistance training (power and strength training as appropriate for their individual goals), and a 10-minute cool-down incorporating yoga and breathing activities. To ensure participants are exercising at the appropriate level of intensity, 1 repetition maximum measures will be used to determine the appropriate levels of resistance and heart rate monitors will be worn.
Study NCT04239911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.
Study NCT04239911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual training course
Description: Virtual training course on heart failure for home health aides.
Study NCT04239911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual training course
Description: Virtual training course on heart failure for home health aides.
Study NCT06564389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07832837
Description: escalated doses of PF-07832837
Study NCT06564389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05068752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID
Study NCT05068752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
Study NCT05743868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Dinner
Description: De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner
Study NCT05743868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Premeal exercise
Description: DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
Study NCT05772390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial breast re-irradiation
Description: partial breast re-irradiation
Study NCT05849454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Messy Memories Intervention
Description: Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory.
Study NCT05003401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HabitAware Keen2
Description: Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
Study NCT05418816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfWrap Bioabsorbable Perivascular Wrap
Description: SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
Study NCT05519241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLZ4-coated paclitaxel-loaded micelles (PPM)
Description: PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity
Study NCT06062290 — intervention group
Intervention type: DEVICE
Intervention: Electromyography (EMG)
Description: Measurement of the compound muscle action potential for the assessment of neuromuscular function
Study NCT06360380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AquaPass System
Description: a treatment session of up to 5 hours with the AquaPass system, evaluating net fluid removal for efficacy analysis and effect on vital signs for safety analysis
Study NCT05107336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Participants will receive subcutaneous injection of AZD2693, once per month.
Study NCT05107336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.
Study NCT05301660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine transdermal patch
Description: 14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
Study NCT05301660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Description: 14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
Study NCT05775367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
Study NCT05916183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid loss and consumption
Description: Upon 5% body mass loss, rehydration of fluid lost to sweating throughout a 2 hour recovery period
Study NCT06038409 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: The efficacy of the various approaches to prescribing Ketamine currently in use off-label. The focus will be to include ketamine within the treatment plan of those with chronic conditions
Study NCT05935670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ischemic Conditioning
Description: The cuff will be placed around the proximal, paretic thigh (or dominant thigh for controls) and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.
Study NCT05296473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHD Therapy
Description: investigational game-play therapy
Study NCT05296473 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: control game-play therapy
Study NCT05992883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Intervention will be an injection containing 1.0 mL of ketorolac 15 mg/mL (15 mg total of ketorolac).
Study NCT05992883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Intervention will be an injection containing 0.5 mL of triamcinolone 40 mg/mL (20 mg total of triamcinolone).
Study NCT05763043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.
Study NCT04576988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.
Study NCT04576988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.
Study NCT04576988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background PAH Therapy
Description: Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Study NCT04576988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background PAH Therapy
Description: Background PAH therapy may consist of the following drug classes: an endothelin-receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, a soluble guanylate cyclase stimulator, and/or a prostacyclin analogue or receptor agonist.
Study NCT05810740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 15 MG
Description: Binimetinib 15 mg tablet
Study NCT05810740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 45 MG
Description: Binimetinib 45 mg tablet
Study NCT05264857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thyroid Nodule Management Education
Description: Participants will receive information about thyroid nodules and their management
Study NCT05499910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NSBAA
Description: The Neuro Strengths-Based Approach to Autism is an approach that teaches people how the autistic brain works and the best practices for providing intervention.
Study NCT06062290 — intervention group
Intervention type: DEVICE
Intervention: Kinemyography (KMG)
Description: Measurement of the muscle velocity for the assessment of neuromuscular function
Study NCT04764461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of customised GROW Charts
Description: Intervention group will follow the same antenatal visit plan and two ultrasounds will be offered (NT 11-13+6 weeks \& anomaly scan 19-22 weeks of gestation) in routine. A third trimester scan will not be offered in routine to Intervention group. Serial SFH measurements will be plotted against estimated date of delivery at each review from 26 weeks of gestation on the customized GROW chart already attached in the maternity notes. On each visit patient will be examined after emptying bladder in a semi-recumbent position, using non-elastic tape with cm side hidden; measurement will be taken from the fundus to upper margin of pubic symphysis. Abnormal SFH measurements, when plotted below the 10th or does not follow its trajectory on customized growth charts will be referred for growth scan suspecting SGA. SFH plotted above 90th centile will also be referred for growth scan, as a part of antenatal care.
Study NCT04490967 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin 1.4% cream will be used on the left side of the face twice daily (home use).
Study NCT04490967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salicylic acid
Description: Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician.
Study NCT05599503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Interventions
Description: Traditional SimpleC Wellness
Study NCT05599503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Interventions
Description: Traditional SimpleC Wellness
Study NCT05599503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot Interventions
Description: Robot interventions
Study NCT05601232 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BNCT
Description: Patients will be infused SPM-011 intravenously at a dose of 200mg/kg/hr over 2 hours. Thereafter, patient will be infused SPM-011 intravenously at a dose of 100mg/kg/hr and will receive neutron irradiation simultaneously for a certain period of time based on his Boronophenylalanine (BPA) concentration in the blood.
Study NCT04836429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Given IV
Study NCT04836429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracic Surgery
Description: Undergo VATS
Study NCT04836429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Undergo photodynamic therapy
Study NCT04836429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative PDT
Description: Subjects will receive one course of light therapy at the time of surgery
Study NCT03838887 — intervention group
Intervention type: DEVICE
Intervention: ultrasound machine
Description: Ultrasound machine with a vocal software
Study NCT05444569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537021
Description: Administered SC.
Study NCT05198869 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral scan
Description: Consenting participants will have a SpotLight-19 scan
Study NCT05428501 — intervention group
Intervention type: OTHER
Intervention: no treatment given
Description: People / Person Living with Obesity (PLwO) Health Care Professionals (HCPs)
Study NCT05444569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Administered SC.
Study NCT04733638 — intervention group
Intervention type: DEVICE
Intervention: Viz ICH VOLUME
Description: Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.
Study NCT04905134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasopharyngoscope
Description: Low-cost, flexible scope prototype will compared to standard of care scope used as standard of care.
Study NCT04959435 — intervention group
Intervention type: OTHER
Intervention: biological samples collection
Description: samples of blood, faeces, saliva, dental plaque, oral mucosa, genital mucosa
Study NCT04523714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online CBT-CP based program
Description: Self-completed, online program in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
Study NCT04523714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual coach-led CBT-CP based program
Description: Live, coach-led program delivered by telephone or videoconference in which participants complete eight, interactive sessions (approximately one per week) focused on training in one or more evidence-based pain coping skills
Study NCT05372757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Heart Transplantation
Description: The donor heart will be recovered and the new heart valve will be removed from this heart by the clinical team. The child will be scheduled for an emergent operation once the donor heart valve is deemed acceptable. The child will have general anesthesia during surgery. This is a state of unconsciousness, which is carefully controlled by the anesthesiologist with a mixture of very potent drugs, to prevent or lessen pain. The child will have a partial heart transplant using the donated heart valve to replace the dysfunctional heart valve. Expected hospital stay will range from weeks to months. The medical care after surgery is performed by the child's clinical team. This type of re-operation could similarly be required after a standard heart valve replacement.
Study NCT05254626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin 10 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; in comparison to pioglitazone.
Study NCT05254626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30 mg
Description: Pioglitazone 30 mg, administered orally and to be prescribed for diabetic and non-diabetic patients with NASH for 24 weeks; as an active control and standard of care treatment.
Study NCT06061094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib 600mg QD plus Chemotherapy
Study NCT06061094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 600mg QD plus Chemotherapy
Study NCT06061094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib 45 mg QD plus chemotherapy
Study NCT06061094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients with molecular failure or intermediate response receive one cycle Blinatumomab before SCT; Patients with molecular CR randomized to the experimental arm receive 3 cycles Blinatumomab + chemotherapy
Study NCT06061094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indication for stem cell transplantation
Description: Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
Study NCT06061094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indication for stem cell transplantation
Description: Patients with molecular CR randomized to the standard arm have an indication for SCT; patients with molecular failure or intermediate response have an indication for SCT. SCT is not part of the trial.
Study NCT05139472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Daily Empagliflozin
Study NCT05619575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1170 sound processor
Description: The CP 1170 sound processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.
Study NCT05619575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CP1150 Sound processor
Description: Active comparator off the ear sound processor.
Study NCT05397145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Study NCT06444568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).